Book Value per Share: Trevi Therapeutics, Inc. (TRVI)

Trevi Therapeutics (TRVI) - corporate logo

The price trajectory of Trevi Therapeutics (TRVI) reflects the dynamics of a company minimizing internal costs by outsourcing clinical trials and formula development to third-party contractors. The business relies on the development of proprietary itch and cough remedies, which will ensure significant pricing power. The current metric stands at 2.24, while the creation of a closed therapeutic cycle around nalbuphine ER makes it difficult for patients to switch to other medications.

Trevi Therapeutics Inc (TRVI) Equity per Share: for the period 07/04/2022 - 10/28/2026

trevitherapeutics.com - analytical breakdowns and key metrics (TRVI)

- price and consensus price forecast:
Stock Quotes Trevi Pharma|TRVI - Price Target Chart
- market capitalization data:
Market Capitalization Trevi Therapeutics, Inc.|TRVI - Company Buyout Price
- book capitalization data:
Net Assets per Single Share Trevi Therapeutics|TRVI - Accounting Capitalization|Market Capitalization to Book Value Ratio trevitherapeutics.com|TRVI - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Trevi Therapeutics|TRVI - Long-Term Debt to Capital|Short-Term Debt to Equity Trevi Therapeutics, Inc.|TRVI - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Trevi Therapeutics, Inc.|TRVI - Long-Term Debt|Company Current Liabilities Trevi Therapeutics
Fundamental company valuation:Trevi Pharma, TRVI
Manufactured products of Trevi Therapeutics, Inc.

Book value per share reflects the portion of equity attributable to a single security after deducting all liabilities. This metric determines the company's actual asset base. For Trevi Therapeutics (TRVI), a niche chronic cough therapy developer, such a base is critical for funding research and development. The trend in book value per share under RAS allows for an assessment of asset resilience against risks. Steady growth in this metric confirms the issuer's long-term solvency.

Competitor analysis

BIIB - Accounting Value per Share|NBIX - Net Assets per Single Share|Regencell Bioscience - Book Value per Share|AXSM (axsome.com) - Net Assets per Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|denalitherapeutics.com - Book Value per Share|Net Assets per Single Share Harmony Biosciences Holdings, Inc. (HRMY)|BHVN: Accounting Value of a Share|Net Assets per Single Share AMLX|Net Asset Value per Share Praxis Corp|Anavex Life Sciences (AVXL) - Accounting Value per Share|Book Price of a Share CBLL|Prothena Biosciences (PRTA) - Net Assets per Single Share|Accounting Value of a Share alector.com (ALEC)|ANNX: Book Value per Share|OMER - Net Asset Value per Share|NGNE - Accounting Value per Share|ACIU - Net Assets per Single Share|Voyager Therapeutics, Inc. - Book Value per Share|Net Assets per Share Neumora|SCLX - Accounting Value per Share|Accounting Value of a Share Tevogen Bio Inc. (TVGN)|Accounting Value per Share Alpha Cognition|Book Price of a Share Cognition Therapeutics Inc. (CGTX)|Book Value per Share Inhibikase Therapeutics, Inc.|Accounting Value of a Share Cassava Sciences Inc SAVA|ASRT (Assertio Therapeutics) - Book Value per Share|COYA: Net Asset Value per Share|Net Assets per Single Share vistagen.com VTGN|Ovid Therapeutics (OVID) - Accounting Value of a Share|ABOS (Acumen Pharmaceuticals, Inc.) - Book Value per Share|Book Value per Share CRVO|ATHE - Net Assets per Single Share|Share Book Value clene.com (CLNN)|PEPG: Book Value per Share|JUNS - Net Asset Value per Share|Relmada Therapeutics, Inc. - Accounting Value per Share|Annovis Bio Inc (ANVS) - Book Value per Share|GRCE - Accounting Value per Share|Firefly Neuro (AIFF) - Book Price of a Share|KLTO: Book Value per Share|Net Assets per Share NeuroSense Therapeutics, Ltd.|Book Value per Share RVPH (Reviva Pharmaceuticals Holdings, Inc.)|Accounting Value per Share MTVA (metaviatx.com)|Net Assets per Single Share NRXS|HSDT - Net Assets per Share|Accounting Value per Share Passage Bio Corp PASG|NEUP: Book Price of a Share|Net Assets per Single Share Minerva Neurosciences, Inc. NERV|Accounting Value of a Share Athira Pharma Inc|Accounting Value per Share Addex Therapeutics, Ltd.|Net Assets per Single Share Alzamend|CYCN (Cyclerion Therapeutics) - Book Value per Share|Net Assets per Share PTIX (protagenic.com)|KTTA - Net Assets per Single Share|Equity per Share Cortigent Inc CRGT|ATXI (Avenue Therapeutics, Inc) - Book Value per Share|BrainStorm Cell Therapeutics Inc. (BCLI) - Net Asset Value per Share|CARA: Accounting Value per Share|CHRO (chromocell.com) - Book Value per Share|ELYM - Net Assets per Single Share|Accounting Value of a Share ITCI|Longboard Pharma - Net Assets per Single Share|Net Asset Value per Share Marinus Pharma MRNS|Accounting Value per Share NKGen Biotech, Inc. (NKGN)|neurobopharma.com - Book Price of a Share|Net Assets per Single Share Sage Therapeutics (SAGE)|SNPX - Accounting Value of a Share|Book Value per Share TRVN|Net Asset Value per Share Vigil Neuroscience, Inc.|Accounting Value per Share Anew Medical|Net Assets per Single Share cerevel.com